0
0
A recent study published in European Neuropsychopharmacology has revealed that low-dose oral ketamine could offer a new and potentially more accessible treatment for post-traumatic stress disorder (PTSD). The research, led by scientists at the University of the Sunshine Coast’s newly established National PTSD Research Centre, suggests that small amounts of ketamine administered in liquid form can significantly reduce PTSD symptoms with fewer side effects compared to traditional intravenous (IV) ketamine treatments.
The open-label clinical trial, the first of its kind to explore the feasibility, safety, and tolerability of oral ketamine for PTSD, involved 22 participants aged 22 to 77. These individuals, many of whom had been living with PTSD for much of their adult lives, received weekly doses of oral ketamine for six weeks. Remarkably, 73% of participants reported a reduction of over 50% in their PTSD symptoms just one week after completing the treatment. One month later, 59% of participants continued to experience symptom relief, highlighting the long-lasting effects of the treatment.
Professor Dan Hermens, the senior investigator on the study, noted that the results of the trial suggest that oral ketamine could be a more accessible and affordable option for PTSD patients. Unlike IV ketamine, which requires administration in a hospital setting, oral ketamine can be delivered in a clinical office, making it a potentially more convenient alternative.
“Despite extensive studies on IV ketamine infusions, there are still gaps in understanding the most effective dosages and administration methods,” said Professor Hermens. “Our study found that oral ketamine, administered in small doses in a clinical setting, is a safe and well-tolerated form of therapy that could be integrated into ongoing PTSD treatment programs.”
Participants also reported significant improvements in their mental health, with reductions in symptoms of depression, stress, and suicidal ideation. Many reported better sleep quality, improved social and occupational functioning, and a noticeable increase in overall well-being. This is particularly significant as over 90% of PTSD patients also struggle with other psychiatric disorders, including anxiety and depression.
Lead author Dr. Bonnie Quigley, a research fellow at the UniSC Thompson Institute, highlighted that oral ketamine has significant advantages over its intravenous counterpart. “Oral ketamine allows for treatment in a doctor’s office, whereas IV ketamine requires a hospital or clinic setting with medical supervision, limiting its use for those with daily or intermittent dosing needs,” Dr. Quigley explained. “Moreover, oral ketamine has fewer side effects, including headaches, dizziness, and feelings of dissociation, which are often reported with IV ketamine.”
The researchers also found that oral ketamine treatment was more affordable than other ketamine treatments, potentially making it more accessible to a wider range of patients.
As the first trial of its kind, the study paves the way for further research into oral ketamine as a treatment for PTSD. The researchers plan to continue exploring optimal treatment strategies to maximize the benefits while minimizing side effects, further validating the promising results of their initial findings.
Disclaimer: This study is still in its early stages and further clinical trials are needed to fully understand the long-term effects and safety of oral ketamine for PTSD treatment. It is essential that individuals consult with a healthcare provider before pursuing any new treatment options.
